Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.44 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.44 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.44 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | GCGR | P47871 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1399864 | 0.99 | PSMB1 (0.46) | MAPK14KDM4ELTA4HMEN1HTT | |
| SCHEMBL1399861 | 0.92 | ALDH1A1 (0.48) | MAPK14KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3100907 | 0.91 | KMT2A (0.47) | MAPK14KDM4EMEN1HTTKMT2A | |
| SCHEMBL1399803 | 0.89 | MAPK14 (0.59) | MAPK14 | |
| SCHEMBL1400018 | 0.89 | MAPK14 (0.47) | MAPK14KDM4EPSMB1PSMB5PSMB2 | |
| SCHEMBL1399746 | 0.88 | MAPK14 (0.58) | MAPK14 | |
| SCHEMBL1399869 | 0.88 | MAPK14 (0.47) | MAPK14KDM4EMEN1HTTKMT2A | |
| SCHEMBL3112375 | 0.87 | JAK2 (0.44) | KDM4EMEN1HTTKMT2APOLB | |
| SCHEMBL1399878 | 0.87 | MAPK14 (0.47) | MAPK14KDM4EPSMB1PSMB5PSMB2 | |
| SCHEMBL3100002 | 0.86 | MAOB (0.45) | KDM4ELTA4HMAOBHRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234355-A1 | ISOQUINOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CYTOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2010-09-16 | — | — | US | disclosed |
| EP-2035386-A1 | ISOQUINOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CYTOKINE MEDIATED DISEASES | AstraZeneca AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| US-20080207596-A1 | Novel compounds 329 | MARTIN BARRIE | 2008-08-28 | — | — | US | disclosed |
| WO-2007149031-A1 | ISOQUINOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CYTOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207596-A1 | Novel compounds 329 | CCL11, IL2, IL1B | MAPK14 1168/4885KDM4E 3798/4885LTA4H 804/4885 |
| US-20100234355-A1 | ISOQUINOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CYTOKINE MEDIATED DISEASES | IL2, IFNG, IL1B | MAPK14 1073/4885KDM4E 3956/4885LTA4H 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.